Abstract
We have learned various data on the role of purinoceptors (P2X4, P2X7, P2Y6 and P2Y12 receptors) expressed in spinal microglia and several factors that presumably activate microglia in neuropathic pain after peripheral nerve injury. Especially P2X4 receptors (P2X4Rs) make a critical contribution to the pain processing. P2X4Rs of microglia might be promising targets for treating neuropathic pain. A predicted therapeutic benefit of interfering with microglial P2X4Rs may be that normal pain sensitivity would be unaffected since expression or activity of most of these receptors are upregulated or enhanced predominantly in activated microglia in the spinal cord where damaged sensory fibers project. Recently, we found that CCL21 regulates the expression of P2X4Rs in different manners, respectively. These new findings also provide novel targets for developing anti-neuropathic pain medicines.
Keywords: P2X4Rs, microglia, neuropathic pain, P2X4Rs, microglia, neuropathic pain, Atomic force microscopy, Brain-derived neurotrophic factor, Chemokine (C-C) ligand 2, Central nervous system, Dorsal root ganglion, Anion reversal potential, Eukaryotic translation initiation factor 4E
CNS & Neurological Disorders - Drug Targets
Title:P2X4 Receptors of Microglia in Neuropathic Pain
Volume: 11 Issue: 6
Author(s): Kazuhide Inoue and Makoto Tsuda
Affiliation:
Keywords: P2X4Rs, microglia, neuropathic pain, P2X4Rs, microglia, neuropathic pain, Atomic force microscopy, Brain-derived neurotrophic factor, Chemokine (C-C) ligand 2, Central nervous system, Dorsal root ganglion, Anion reversal potential, Eukaryotic translation initiation factor 4E
Abstract: We have learned various data on the role of purinoceptors (P2X4, P2X7, P2Y6 and P2Y12 receptors) expressed in spinal microglia and several factors that presumably activate microglia in neuropathic pain after peripheral nerve injury. Especially P2X4 receptors (P2X4Rs) make a critical contribution to the pain processing. P2X4Rs of microglia might be promising targets for treating neuropathic pain. A predicted therapeutic benefit of interfering with microglial P2X4Rs may be that normal pain sensitivity would be unaffected since expression or activity of most of these receptors are upregulated or enhanced predominantly in activated microglia in the spinal cord where damaged sensory fibers project. Recently, we found that CCL21 regulates the expression of P2X4Rs in different manners, respectively. These new findings also provide novel targets for developing anti-neuropathic pain medicines.
Export Options
About this article
Cite this article as:
Inoue Kazuhide and Tsuda Makoto, P2X4 Receptors of Microglia in Neuropathic Pain, CNS & Neurological Disorders - Drug Targets 2012; 11 (6) . https://dx.doi.org/10.2174/187152712803581065
DOI https://dx.doi.org/10.2174/187152712803581065 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science The Novel Synthesized Pyridazinone Derivates had the Antiproliferative and Apoptotic Effects in SHSY5Y and HEP3B Cancer Cell Line
Letters in Organic Chemistry Nanoparticles vs Cancer: A Multifuncional Tool
Current Topics in Medicinal Chemistry Recent Patents Relating to Tumor Suppressor Genes
Recent Patents on DNA & Gene Sequences New Adamantane Derivatives with Sigma Affinity and Antiproliferative Activity
Medicinal Chemistry Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
Current Molecular Medicine Regulation of Calcium Signaling by the Second Messenger Cyclic Adenosine Diphosphoribose (cADPR)
Current Molecular Medicine Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine
Current Genomics Amyloid-β Aggregation Inhibitory and Neuroprotective Effects of Xanthohumol and its Derivatives for Alzheimer’s Diseases
Current Alzheimer Research Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors
Current Drug Metabolism Triterpenoid Saponins from Two Panax japonicus Varietals Used in Tujia Ethnomedicine
Current Traditional Medicine Endomorphin Derivatives with Improved Pharmacological Properties
Current Medicinal Chemistry Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Mitochondrial Respiration in the Platelets of Patients with Alzheimer’s Disease
Current Alzheimer Research Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review
Mini-Reviews in Medicinal Chemistry Potential Photochemical Interactions of UV Filter Molecules with Multichlorinated Structure of Prymnesins in Harmful Algal Bloom Events
Mini-Reviews in Organic Chemistry